Michos Erin D, Vasamreddy Chandrasekhar R, Becker Diane M, Yanek Lisa R, Moy Taryn F, Fishman Elliot K, Becker Lewis C, Blumenthal Roger S
Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Am Heart J. 2005 Dec;150(6):1276-81. doi: 10.1016/j.ahj.2005.02.037.
The Framingham risk estimation (FRE) serves as the basis for identifying which asymptomatic adults should be treated with aspirin and lipid-lowering therapy in primary prevention. However, the FRE generally yields low estimates of 10-year "hard" coronary heart disease (CHD) event risk with few women (< 70 years) qualifying for preventive pharmacologic therapy despite relatively high lifetime risk. We postulated that traditional risk factor assessment might fail to identify a sizeable portion of women with a sibling history for premature CHD as having advanced subclinical atherosclerosis.
We studied 102 asymptomatic women (mean age 51 +/- 7 years) who were the sisters of a proband hospitalized with documented premature CHD. Participants underwent risk factor assessment and multidetector computed tomography for coronary artery calcium (CAC) scoring. Based on FRE prediction of 10-year risk for hard CHD events, participants were classified as low risk (< 10%) (n = 100), intermediate risk (10%-20%) (n = 2), or high risk (> 20%) (n = 0). Significant subclinical atherosclerosis was defined as age-sex adjusted > 75th percentile CAC scores.
Ninety-eight percent were at low risk (mean FRE of only 2% +/- 2%). However, 40% had detectable CAC, 12% had CAC > 100, and 6% had CAC > or = 400. Based on CAC score percentiles, 32% had significant subclinical atherosclerosis and 17% ranked above the 90th percentile.
Among women classified as low risk by FRE, a third had significant subclinical atherosclerosis. Sisters of probands with premature CHD appear to be a high-risk group and may warrant noninvasive screening for subclinical atherosclerosis to appropriately target individuals for more aggressive primary prevention therapy than what is currently recommended.
弗雷明汉风险评估(FRE)是确定在一级预防中哪些无症状成年人应接受阿司匹林和降脂治疗的基础。然而,FRE通常对10年“严重”冠心病(CHD)事件风险的估计较低,尽管女性终生风险相对较高,但很少有70岁以下的女性符合预防性药物治疗的标准。我们推测,传统的风险因素评估可能无法识别出相当一部分有早发性冠心病家族史的女性患有晚期亚临床动脉粥样硬化。
我们研究了102名无症状女性(平均年龄51±7岁),她们是因记录在案的早发性冠心病而住院的先证者的姐妹。参与者接受了风险因素评估和冠状动脉钙化(CAC)评分的多排螺旋计算机断层扫描。根据FRE对严重CHD事件10年风险的预测,参与者被分类为低风险(<10%)(n = 100)、中度风险(10%-20%)(n = 2)或高风险(>20%)(n = 0)。显著亚临床动脉粥样硬化定义为年龄和性别调整后CAC评分高于第75百分位数。
98%的人处于低风险(平均FRE仅为2%±2%)。然而,40%的人可检测到CAC,12%的人CAC>100,6%的人CAC≥400。根据CAC评分百分位数,32%的人有显著亚临床动脉粥样硬化,17%的人排名高于第90百分位数。
在被FRE分类为低风险的女性中,三分之一有显著亚临床动脉粥样硬化。有早发性冠心病先证者的姐妹似乎是一个高风险群体,可能需要对亚临床动脉粥样硬化进行无创筛查,以便比目前推荐的更积极地针对个体进行一级预防治疗。